Artificial intelligence firm twoXAR raises $10M for partnering drive


Artificial intelligence company twoXAR--a specialist in separating signals from noise in data-rich drug discovery projects--has raised $10 million in a first-round financing led by SoftBank Ventures. Co-founder and CEO Andrew Radin says the proceeds will be used to bring forward preclinical drug candidates including candidates for diabetes, liver cancer and rheumatoid arthritis, build the pipeline with new partnering deals and spinouts, and add to its headcount. The company's business model is to use its AI technology to identify promising drug candidates, validate them through preclinical studies and then work with partners to bring them into the clinic. The Palo Alto, California-based company--which was the first investment for Silicon Valley entrepreneur Andreessen Horowitz's $200 million biotech fund in 2015--already has some collaborations under its belt. In 2016, it signed deals with the Universities of Chicago and Stanford for drug discovery programs in atherosclerosis and liver disease, respectively, as well as Mount Sinai Medical in the area of diabetic neuropathy.

Sweetch's AI-driven app claims to reduce risk of developing diabetes


While the world tries to decide whether artificial intelligence is here to help us or hurt us, AI is quietly infiltrating our daily lives -- from streaming recommendations to image recognition. And in health technology, AI is making a real difference to people across the world, saving lives in a multitude of ways. Today Sweetch -- a mobile health app that helps prevent diabetes and improve outcomes for people with diabetes by encouraging long-term behavioral change -- has revealed the outcomes of its clinical trial conducted at Johns Hopkins University. Directed by the university's division of endocrinology, diabetes, and metabolism, the study shows that using Sweetch significantly lowered A1C levels -- a diabetes biomarker for blood sugar. The app has been shown to increase physical activity and reduced weight for patients with early stage diabetes.

In the future, an AI may diagnose eye problems - FeedBox


The computer will see you now. Artificial intelligence algorithms may soon bring the diagnostic know-how of an eye doctor to primary care offices and walk-in clinics, speeding up the detection of health problems and the start of treatment, especially in areas where specialized doctors are scarce. The first such program -- trained to spot symptoms of diabetes-related vision loss in eye images -- is pending approval by the U.S. Food and Drug Administration. While other already approved AI programs help doctors examine medical images, there's "not a specialist looking over the shoulder of [this] algorithm," says Michael Abràmoff, who founded and heads a company that developed the system under FDA review, dubbed IDx-DR. "It makes the clinical decision on its own."

Artificial Intelligence and the Move Towards Preventive Healthcare - insideBIGDATA


In this special guest feature, Waqaas Al-Siddiq, Founder and CEO of Biotricity, discusses how AI's ability to crunch Big Data will play a key role in the healthcare industry's shift toward preventative care. A physicians' ability to find the relevant data they need to make a diagnosis will be augmented by new AI enhanced technologies. Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council. Waqaas has a dual Bachelor's degree in Computer Engineering and Economics, a Master's in Computer Engineering from Rochester Institute of Technology, and a Master's in Business Administration from Henley Business School. He is completing his Doctorate in Business Administration at Henley, with a focus on Transformative Innovations and Billion Dollar Markets.

Smart watches are using artificial intelligence to detect diabetes


Wearable devices can be used to detect the early signs of diabetes using an artificial intelligence (AI) network called DeepHeart and developed by Cardiogram, a study has found. Some 32m people in the US have diabetes, while a further 70m people are thought to be living with so-called pre-diabetes, according to GlobalData figures. With 88 percent of people who are pre-diabetic unaware of their condition, and one in four cases of diabetes going undiagnosed, DeepHeart could provide an easy and affordable means of diagnosing a condition with ever-increasing societal importance. The combination of AI and smart watches is another win for tech giants Apple and Google, as they continue to explore the realm of digital health. Apple's intentions to become a key player in the healthcare space are clear.

Researchers Identify Five Different Types of Diabetes, Not Just Two


For many years, diabetes cases have largely been classified as either type 1 or type 2. But a new study suggests that there may actually be five different types of the disease--some of which may be more dangerous than others. A new classification system could help doctors identify the people most at risk for complications, the study authors say, and could pave the way for more personalized and effective treatments.

A 'paradigm shift' in the diagnosis of diabetes: study

The Japan Times

PARIS – Scientists on Friday unveiled a revised classification for diabetes, one they said could lead to better treatments and help doctors more accurately predict life-threatening complications from the disease.

Machine Learning Healthcare Applications - 2018 and Beyond


In the broad sweep of AI's current worldly ambitions, machine learning healthcare applications seem to top the list for funding and press in the last three years.